Abstract | BACKGROUND: METHODS: We performed a flow cytometric analysis on peripheral blood mononuclear cells (PBMC); we collected from 23 healthy donors and 225 MS patients: untreated (n = 19) or treated with NTZ (n = 113), interferon-beta (n = 26), glatiramer acetate (n = 26), fingolimod (n = 23) and rituximab (n = 18). We have also analysed two PML/IRIS ( immune reconstitution inflammatory syndrome) patients and four longitudinal samples of a NTZ-treated patients before and during the development of a clinical asymptomatic magnetic resonance imaging (MRI) lesion confirmed as PML by cerebrospinal fluid (CSF) examination. Thirty-five NTZ-treated patients were studied longitudinally with three samples taken 4 months apart. RESULTS: The NTZ-treated patients showed a lower percentage of CD62L (33.68%, n = 113) than first-line treated patients (44.24%, n = 52, p = 0.0004). NTZ effect was already clear during the first year of treatment (34.68 ; p = 0.0184); it persisted in the following years and disappeared after drug withdrawal (44.08%). Three percent of longitudinally analysed patients showed a percentage of CD62LCD4+ T cells under a hypothetical threshold and one patient with asymptomatic PML belongs to a group which expressed low percentage of CD62LCD4+ T cells. CONCLUSIONS: Our research confirms that NTZ has a specific effect on CD62LCD4+ T cells consisting in decreasing of the number of positive cells. The low level of CD62L found in a clinically asymptomatic PML patient strengthens its potential usefulness as a biomarker of high PML risk in NTZ-treated patients. A larger study is required to better confirm the data.
|
Authors | Michela Spadaro, Marzia Caldano, Fabiana Marnetto, Alessandra Lugaresi, Antonio Bertolotto |
Journal | Journal of neuroinflammation
(J Neuroinflammation)
Vol. 12
Pg. 146
(Aug 12 2015)
ISSN: 1742-2094 [Electronic] England |
PMID | 26259673
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunologic Factors
- Natalizumab
- L-Selectin
- Rituximab
- Glatiramer Acetate
- Interferon-beta
- Fingolimod Hydrochloride
|
Topics |
- Adult
- Aged
- CD4-Positive T-Lymphocytes
(drug effects, metabolism)
- Female
- Fingolimod Hydrochloride
(pharmacology)
- Glatiramer Acetate
(pharmacology)
- Humans
- Immune Reconstitution Inflammatory Syndrome
(cerebrospinal fluid, drug therapy, immunology)
- Immunologic Factors
(pharmacology)
- Interferon-beta
(pharmacology)
- L-Selectin
(biosynthesis)
- Leukocyte Count
- Male
- Middle Aged
- Monocytes
(drug effects)
- Multiple Sclerosis
(drug therapy)
- Natalizumab
(pharmacology)
- Rituximab
(pharmacology)
- Young Adult
|